us health care professional perspectives on adverse drug ... · us health care professional...

US Health Care Professional Perspectives on Adverse Drug Event Reporting in the Hospital Setting and the

Opportunity for Information Technology

Gustavo Grampp Amgen Inc.

!Stella Stergiopoulos, Tufts CSDD; Carrie A. Brown, Tufts University;

Thomas Felix, Amgen Inc.; Kenneth A. Getz; Tufts CSDD

Disclosure - !"#$%#&#'%("$)#&(%*+#)$*,$-"*&$.%#&#,-'/0,$1'&$&2..0%-#)$+3$'$4%',-$5%06$764#,$8,(9$-0$!2:&$;#,-#%$50%$-"#$<-2)3$05$=%24$=#>#?0.6#,-9$$8,-#%.%#-'/0,&$.%0>*)#)$%#.%#&#,-$-"#$&"'%#)$.#%&.#(/>#&$05$-"#$'2-"0%&9$

"!

What is the role of health information technology (HIT) in pharmacovigilance?

•! #$%&'(!)%*!+,!-!+-../,.!*%!.,0%.1)2!-(3,.4,!(.&2!,3,)*4!567849!•! #$%&'(!'/):!0-1,)*!;-.,<!0$-.=-;>!-)(!/)41*&1%)-'!4-?,*>!4>4*,=4!

•! @(,)1A-+',!0-1,)*<!.,0%.*-+',!,3,)*<!4&40,;*!(.&2!540%)*-),%&4!.,0%.*49!

•! #$%&'(!;%=0'>!B/*$!2%3,.)=,)*!0%'/;/,4!-)(!4*-)(-.(4!

•! C.%(&;*D40,;/A;!-)(!+-*;$D40,;/A;!*.-;:/)2!%?!+/%'%2/;-'!0.%(&;*4!

E!

Tufts CSDD 2014 Survey of ADE Reporting Practices in the US

F! @)*,.3/,B,(!GG!,H0,.*4!/)!=,(/;/),<!0$-.=-;>!-)(!/)(&4*.>!

F! I-00,(!678!.,0%.1)2!0.%;,44!J%B4!-)(!K@L!4>4*,=4!/)!$%40/*-'4<!;'/)/;4!-)(!0$-.=-;/,4!

C$-4,!G!

F! M.,-*,(!-)(!(/4*./+&*,(!4&.3,>!/)4*.&=,)*!*%!N#!0.-;11%),.4!/)!3-./%&4!4,O)24!5$%40/*-'<!0$-.=-;><!;'/)/;9!

F! P,;,/3,(!QR!.,40%)4,4!?.%=!$%40/*-'!0.-;11%),.4!50$-.=-;/4*4<!I74<!)&.4,49!

C$-4,!"!

S!

!"#$%&'()*+,--'.&*/'%"0'1%2'3"%&4-#-'

56%"$74#"8'9:,'(%)$,-'%"0';4-9,<-'#"=*&=,0'#"'3>?'@,2*)$"8'

C.-;1;,!.,'-*,(!A)(/)24!-.,!0.,4,)*,(!/)!(*-9,)'(ABC'-*!*$/4!;%)?,.,);,T!

Phase 1 findings related to HIT: Many systems are used in typical hospital practice

8',;*.%)/;!#>4*,=4!

8KPU8IP!

MCV8!

,I6P!

WMI6!

WMIC!

@P!

X!

?&,+9)*"#+';4-9,<-'

8KPU!8IP' 8',;*.%)/;!K,-'*$!P,;%.(4U8',;*.%)/;!I,(/;-'!P,;%.(4!

MCV8' M%=0&*,./Y,(!C$>4/;/-)!V.(,.!8)*.>!4>4*,=!

,I6P' 8',;*.%)/;!I,(/;-1%)!6(=/)/4*.-1%)!P,;%.(!

WMI6' W-.;%(,D,)-+',(!I,(/;-1%)!6(=/)/4*.-1%)!

WMIC' W-.DM%(,!I,(/;-1%)!C.,0-.-1%)!L,;$)%'%2/,4!@P' 8',;*.%)/;!/);/(,)*!.,0%.1)2!4>4*,=!

Phase 2: Survey findings identified a typical Hospital-based ADE reporting process flow

Z!

7.&2!#&40,;*,(!

7.&2!-)(!68!7%;&=,)*,(!/)!C-1,)*!P,;%.(4!

P,*./,3,!7,*-/'4!-+%&*!*$,!7.&2!

P,*./,3,!7,*-/'4!-+%&*!*$,!6(3,.4,!

83,)*!

P,0%.*!6(3,.4,!83,)*!

7.&2!-)(!68!7%;&=,)*,(!/)!@)*,.)-'!@);/(,)*!P,0%.*!

I%4*!.,40%)(,)*4!$-3,!4&+=/[,(!/)*,.)-'!.,0%.*4!5RS\9<!+&*!=-)>!$-(!-'4%!.,0%.*,(!*%!]76!5XG\9!%.!-!=-)&?-;*&.,.!5EX\9^!

^!_&,41%)!B-4!`L%!B$/;$!%?!*$,!?%''%B/)2!%.2-)/Y-1%)4!$-3,!>%&!.,0%.*,(!-)!678a!54,',;*!-''!*$-*!-00'>9b!5)c!XR9!

R!

Phase 2 survey identified key factors preventing ADE reporting in Hospitals!"

D!E'),&%9,0'

@2#&/0,$'&A#)B$CD'&#)$0,$302%$#E.#%*#,(#F$"01$0:#,$)0$#'("$05$-"#&#$%#'&0,&$.%#>#,-$"#'?-"$('%#$.%0>*)#%&$5%06$%#.0%/,4$7=G&$-0$-"#$H=7$0%$-"#$6',25'(-2%#%IJ$5)!c!QR9!

Lack of system integration was cited as a significant reason for not reporting ADEs (52%)*

d,>!(,*-/'4!-.,!40.,-(!-=%)2!=&'10',!(-*-!4%&.;,4!

•!7.&2!(,*-/'4!40.,-(!-;.%44!S!%.!=%.,!4%&.;,4!5SZ\<!)cRS9!

•!678!(,*-/'4!40.,-(!-;.%44!E!%.!=%.,!4%&.;,4!5XG\<!)cZe9!!

Q!

>)68'0,9%#&-'' 3>?'0,9%#&-',I6P!5Ee\9' 8KP!U!8IP!5S"\9'

8KP!U!8IP!5EX\9' @P!#>4*,=!5Ef\9'MCV8!5"X\9'

V*$,.!)%)DK@L!4%&.;,4g!!!C$-.=-;>!5ER\9!!!C-1,)*!M$-.*!5"Q\9!!!C-0,.!+-4,(!@P!5G"\9$

V*$,.!)%)DK@L!4%&.;,4g!!!C-1,)*!;$-.*!5SS\9!!!M-.,!2/3,.!5"Q\9!!!C-0,.!+-4,(!@P!5GG\9$

@,2*)9,0'-*6)+,-'7*)'0,9%#&-''FG'*7'),-2*"0,"9-H'

^_&,41%)!B-4!!`W-4,(!%)!>%&.!,H0,./,);,<!$%B!%h,)!(%!,-;$!%?!*$,4,!.,-4%)4!0.,3,)*!$,-'*$!;-.,!0.%3/(,.4!?.%=!.,0%.1)2!6784!*%!*$,!]76!%.!*$,!=-)&?-;*&.,.a!`!5)cQR9!

Limited availability of important drug data elements in HIT systems

e!i%*,g!i!c!ZET!!_&,41%)!B-4!`j$/;$!%?!*$,!?%''%B/)2!(-*-!-+%&*!*$,!0-.1;&'-.!(.&2!-(=/)/4*,.,(!*%!-!0-.1;&'-.!0-1,)*!-.,!.%&1),'>!-3-/'-+',!/)!>%&.!,',;*.%)/;!4>4*,=4ab!

•! I-)&?-;*&.,.!5A,'(!%.!i7M!;%(,9!-)(!'%*!/(,)1A,.4!-.,!4;-.;,!/)!=%4*!4>4*,=4!•! W-.!;%(,!+-4,(!4>4*,=4!=->!/=0.%3,!(-*-!;-0*&.,!

IJE?K'I>L'/#&&'M,'6-,0'%-'9:,'N;'2)*06+9'#0,"$O,)'#"''9:,'!;J'!>P('

Could HIT impact drug identification in other countries? #$%&!'()*+,!-.!/0123'4!4-'03516'!'4-7+8!5415!'-9+!+:0)+';)3<32=!','5+9'!+2;-()1=+!-)!)+>(3)+!?@@!0)+';)3<32="

Gf!

6.,!4&;$!4>4*,=4!;%=0-1+',!B/*$!*$,!8M!Ck!(/.,;13,a!`!"#!$#%%$#&&'(&')#!*$+*#,-'*,$#'*$!#.*/$!($)0*/123$4%*#'%3$#/3$5)(%(6)4#%$+*0)4)/#%$&'(0-4!$&'*,4')5*07$8)!"$0-*$'*6#'0$!($!"*$/#+*$(2$!"*$+*0)4)/#%$&'(0-4!bG!!

G!M%&);/'!7/.,;13,!"fGfUQSU8M<!-.*T!Gf"5,9<!"fGf!VTlT!5m!ESQ9!RS<!QS!5-=,)(/)2!M%&);/'!7/.,;13,!"ffGUQSU8M9T!

!!

='-'$(02%-#&3$05$H'%6'*,)2&-%*'$E*9%&'M,0-K'QRSTUV'

Can the medicines be looked for by brand?

Is INN only predefined in a drop down menu so that the doctor can select it?

Summary and Discussion

•! K%40/*-'!@L!4>4*,=4!-.,!-)!,44,)1-'!4%&.;,!?%.!.,;%.(/)2!-)(!.,*./,3/)2!678!-)(!4&40,;*!(.&2!/)?%.=-1%)!

•! C.,4,);,!%?!=&'10',!4>4*,=4!*$-*!'-;:!/)*,2.-1%)!=->!+,!-)!%+4*-;',!*%!,n;/,)*!678!.,0%.1)2!

•!I-)>!4>4*,=4!=->!)%*!;-0*&.,!(.&2!/(,)1A,.4!%*$,.!*$-)!+.-)(!-)(U%.!@ii!

•! P,;%==,)(-1%)4g!•! @=0.%3,!-;;,44!*%!/)?%.=-1%)g!!@)*,.%0,.-+/'/*>U/)*,2.-1%)!%?!(.&2!/(,)1A,.4!-)(!678!(-*-!?.%=!=&'10',!4>4*,=4!

•! #>4*,=!(,4/2)4!4$%&'(!0,.=/*!&4,!%?!+.-)(!)-=,4!?%.!+/%'%2/;4!•! @)*,2.-*,!0.%(&;*D40,;/A;!(-*-!?.%=!+-.!;%(,!+-4,(!4>4*,=4!/)*%!%*$,.!K@L!4>4*,=4!*%!/=0.%3,!'%*D',3,'!*.-;,-+/'/*>!

GG!

Limitations

•! L$,!=-o%./*>!%?!$%40/*-'!+-4,(!4&.3,>!.,40%)4,4!%./2/)-*,(!?.%=!E!N#!4*-*,4!5i,B!p%.:<!i,B!l,.4,><!j-4$/)2*%)9!

•! "E\!%?!$%40/*-'!.,40%)(,)*4!5)cX"9!$-(!),3,.!.,0%.*,(!-)!678!5/)*,.)-''>!%.!,H*,.)-''>9!

•! SQ\!$-(!),3,.!.,0%.*,(!-)!678!*%!]76!%.!-!=-)&?-;*&.,.!

G"!

Thank you! q&4*-3%!q.-=00!

6=2,)!@);T!

About the Tufts CSDD

•! M,)*,.!-*!L&h4!N)/3,.4/*>!#;$%%'!%?!I,(/;/),!5$[0gUU;4((T*&h4T,(&9!

•! @)(,0,)(,)*<!-;-(,=/;!2.%&0!?%;&4/)2!%)!(.&2!(,3,'%0=,)*!4;/,)1A;<!.,2&'-*%.><!,;%)%=/;!-)(!=-)-2,=,)*!0%'/;>!

•! q.-)*!?&)(,(!-)(!5;.%44D/)(&4*.>9!40%)4%.,(!4*&(/,4!!

•! P,4&'*4!$-3,!/)?%.=,(!M%)2.,44<!*$,!i-1%)-'!6;-(,=/,4!%?!#;/,);,<!]%&)(-1%)4<!@)(&4*.><!M-0/*-'!I-.:,*!-)-'>4*4!-)(!/)3,4*%.4<!P,2&'-*%.>!62,);/,4<!*$,!i-1%)-'!@)41*&*,4!%?!K,-'*$!

GS!

Tufts CSDD: Furthering the Cause of Pharmaceutical Innovation

!!!!!!

Staff Presentations

Louis Lasagna Library of Drug Development

Electronic Databases &

Bibliographies

!!Sponsorship

!!!

Surveys & Questionnaires

Information Services

Multi-Company Project Series

!!

Manuscripts, White Papers & Book Chapters

!

Research and Publications

!

Industry Programs

Sponsored Research Projects

!!!

Commentaries & Editorials

Tufts CSDD Executive

Forum !!

Public Hearings & Testimony

!

Tufts Center for the Study of Drug Development

Quarterly Updates

!!

Bi-Monthly Impact Report

T U F T S U N I V E R S I T Y !Annual

Postgraduate Course

!!!

Annual Outlook Report

!

Subscription- Based Reports

!

Training & Workshops

Annual Leadership

Course !!!

Quarterly R&D Mgmt. Report

!!

Webinars, Wkshps., & R&D

Roundtables